Wire · opportunities
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
Oncolytics Biotech published data demonstrating that pelareorep can convert immunologically inactive liver tumors into ones responsive to immunotherapy by altering the tumor microenvironment and increasing key immune markers. This supports pelareorep's potential as a backbone therapy to enhance the effectiveness of immune-based cancer treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 29 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
You can now consider pelareorep as a proven way to activate tough-to-treat liver tumors for immunotherapy combinations. Your next step is exploring partnerships or trials that leverage pelareorep to unlock immune response in previously resistant cancers.
◆ Coverage
2 sources · first reported 29 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics